cisplatin, and Nab-paclitaxel for resectable BTC.Methods:Resectable, treatment-nave BTC patients (pts) were enrolled and administered 3 cycles of neoadjuvant durvalumab (1000mg, iv, d1, q3w) + GAP (gemcitabine 1000mg/m2, cisplatin 25mg/m2, Nab-paclitaxel 100mg/m2, d1, d8, 21d cycle). ...
2.Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. doi:10.1056/EVIDoa2200015 3.FDA approves durvalumab for locally advanced or metastatic biliary tract cancer. FDA. September 2, 2022. Accessed ...
The FDA has approved durvalumab (Imfinzi) in combination with gemcitabine and cisplatin in adult patients with locally advanced or metastatic biliary tract cancers.1 The regulatory decision was supported by findings from the phase 2 TOPAZ-1 trial (NCT03875235), in which durvalumab ...
2.Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. doi:10.1056/EVIDoa2200015 3.FDA approves durvalumab for locally advanced or metastatic biliary tract cancer. FDA. September 2, 2022. Accessed ...
"After 3 years of follow-up, durvalumab plus gemcitabine and cisplatin continued to demonstrate clinically meaningful long-term survival benefit with an acceptable safety profile, further supporting its use as a standard-of-care treatment in patients with locally advanced or metastatic biliary tract can...
Background:Immunotherapies have shown clinical activity in patients with advanced biliary tract cancer, for which outcomes remain poor despite standard of care treatment with gemcitabine and cisplatin. We aimed to evaluate gemcitabine and cisplatin plus durvalumab with or without tremelimumab as first-line...
IMFINZI is also approved in combination with chemotherapy (gemcitabine plus cisplatin) in locally advanced or metastatic biliary tract cancer and in combination with tremelimumab-actl in unresectable hepatocellular carcinoma (HCC). IMFINZI is also approved as a monotherapy in unresectable HCC inJapa...
2 The trial evaluated a treatment of neoadjuvant durvalumab plus gemcitabine/cisplatin followed by radical cystectomy then durvalumab as a monotherapy compared with neoadjuvant gemcitabine/cisplatin alone followed by radical cystectomy in cisplatin-eligible patients with MIBC. “New options for [MIBC] are ...
2. Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. Published online June 1, 2022. doi: 10.1056/EVIDoa2200015 3. First phase III trial in this setting to show improved overall survival with an ...
IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). IMFINZI in combination with IMJUDO is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC)...